Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 201.00
Bid: 199.20
Ask: 203.50
Change: 3.80 (1.93%)
Spread: 4.30 (2.159%)
Open: 199.00
High: 202.50
Low: 194.20
Prev. Close: 197.20
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Thu, 15th Apr 2021 09:00

(Alliance News) - Oxford BioMedica PLC on Thursday reported a surge in revenue for 2020 and looked to further strong growth in the year ahead.

Revenue for 2020 jumped 37% to GBP87.7 million from GBP64.1 million the year before, while the gene and cell therapy company's pretax loss slimmed substantially to GBP6.6 million from GBP20.9 million.

Notably, Oxford BioMedica in 2020 became a key manufacturer of the Oxford-AstraZeneca PLC Covid-19 vaccine.

Having signed an initial agreement in May, Oxford BioMedica signed an 18-month supply agreement in September under a three-year master supply and development agreement for the large-scale manufacture of the Oxford-AstraZeneca vaccine. Oxford BioMedica received a GBP15 million capacity reservation fee with additional revenue in excess of GBP35 million expected by the end of 2021.

Further to this, Oxford BioMedica expects an increase in underlying LentiVector platform based revenue in 2021 from both bioprocessing and commercial development activities.

"It is therefore expected that revenues for the group should grow strongly in 2021," the firm said.

At an operating earnings before interest, tax, depreciation and amortisation level for the year ahead, Oxford BioMedica expects an increase from 2020, though at a more modest rate than revenue due to increased research and development spend as it invests for the future.

The company reported operating Ebitda of GBP7.3 million for 2020, swinging from a loss in 2019 of GBP5.2 million.

"I am truly proud of the group's achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for Covid-19," said Chief Executive John Dawson.

"Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the group's leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners' programmes."

Shares in Oxford BioMedica were up 0.8% at 1,048.00 pence in London on Thursday. The stock is up more than 50% over the past 12 months.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Mar 2024 16:22

Oxford Biomedica shares rise on post-acquisition guidance

(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.

Read more
5 Mar 2024 08:57

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Feb 2024 11:34

EnSilica hires new chief financial officer from Oxford Biomedica

(Alliance News) - EnSilica PLC on Monday said it has appointed a new chief financial officer, who will join the company and board in May.

Read more
29 Jan 2024 12:35

IN BRIEF: Institut Merieux ups stake in Oxford BioMedica toward 10%

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the partnership between Oxford BioMedica and Institut Merieux. ABL is a cell and gene therapy contract development and manufacturing organization with facilities in Lyon and Strasbourg in France. For the EUR15 million acquisition, Oxford BioMedica will issue 3.1 million new shares to Lyon-based Institut Merieux at a price of 407.4 pence, well above its current market price. This is a 3.2% stake, and Institut Merieux already had 3.3%, giving it a total 6.5% holding. Oxford BioMedica says Institut Merieux intends to raise this to 10.0% by the end of the September.

Read more
7 Dec 2023 21:10

Oxford BioMedica posts optimistic outlook on uptick in contract value

(Alliance News) - Oxford BioMedica PLC on Thursday said it is on track to achieve its guidance for the year, amid an uptick in current contracted value and growth supported by new orders.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
4 Dec 2023 10:32

Oxford BioMedica buys ABL Europe for consideration of EUR15 million

(Alliance News) - Oxford BioMedica PLC on Monday said that it has entered a sale and purchase agreement with TSGH SAS for the acquisition of ABL Europe SAS.

Read more
20 Oct 2023 10:02

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
18 Oct 2023 09:39

LONDON BROKER RATINGS: Citigroup cuts Wizz Air to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
27 Sep 2023 11:24

Director dealings: TUI, Oxford Biomedica board members linked to buys

(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.

Read more
22 Sep 2023 09:33

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
21 Sep 2023 09:40

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
20 Sep 2023 12:21

Oxford BioMedica shares up, in talks to buy ABL Europe but loss widens

(Alliance News) - Oxford BioMedica PLC on Wednesday said loss widened in the first half of 2023 as revenue fell, while it noted being in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15 million.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.